Molecular fingerprinting of Pseudomonas aeruginosa from PWCF, and a UK reference laboratory investigation into frequency of cross-infection
Ivacaftor impacts nutrition and growth status in 4 to 24 month old children within the first 12 weeks
Successful treatment of a blockage in the lower portion of the small intestine in patients with cystic fibrosis using a solution administered during a colonoscopy.
Changes in weight and how much you eat after starting triple modulator therapy in adults with cystic fibrosis
Weight A Minute: Exploring the effect on total weight, fat and fat-free weight after the initiation of Elexacaftor/ Tezacaftor/ Ivacaftor in adults with CF
Elexacaftor/Tezacaftor/Ivacaftor improves CFTR activity and pulmonary function in Cystic Fibrosis Patients carrying the N1303K Mutation
